>The market seems to like the [I-vation] news (up 5%).<
Indeed they do, and this is not unreasonable given that safety was the primary goal of the STRIDE trial.
But I have to assume that SRDX had hoped for a somewhat stronger showing of efficacy. The data are consistent with some of the InnoRx selling that we’ve talked about at length on this board. JMHO, FWIW
Market Data 
Markets 
AI
